Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

Cantor Fitzgerald has recently initiated Aquestive Therapeutics Inc (AQST) stock to Overweight rating, as announced on December 17, 2024, according to Finviz. Earlier, on May 10, 2024, Leerink ...

Leerink downgraded Accolade (ACCD) to Market Perform from Outperform with a price target of $7.03, down from $9.50, after the company agreed to ...

Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing ...

Align Technology (NASDAQ:ALGN – Get Free Report) was upgraded by investment analysts at Leerink Partnrs from a “hold” rating ...

Equities research analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for Geron in a note issued ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

Beta Bionics (BBNX), a maker of insulin delivery devices, has filed for a $100M initial public offering.  Read more here.

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from ...

Align Technology upgraded by Leerink Partners with a $280 price target, citing growth potential, stock buyback plans, and global market expansion.